Summary of PTC Therapeutics Q3 2025 Earnings Call

1Key Financial Results and Metrics

Total Revenue: $211 million for Q3 2025.

Sephience Revenue: $19.6 million generated since its launch, with $14.4 million from the U.S. and $5.2 million internationally.

DMD Franchise Revenue: $86 million, with Translarna contributing $51 million and Emflaza $35 million.

Royalty Revenue: $71 million from Roche's Evrysdi, which generated $532 million globally.

Cash Position: Approximately $1.68 billion in cash, enabling the company to reach cash flow breakeven and pursue strategic opportunities.

2Strategic Updates and Business Highlights

Sephience Launch: Initiated global launch in Europe and the U.S., with positive early momentum and 521 patient start forms received from U.S. centers.

Clinical Data: Presented results showing Sephience's efficacy, with a 70% greater reduction in phenylalanine levels compared to BH4 in the AMPLIFY study.

Regulatory Updates: Meetings planned with the FDA for the votoplam Huntington's disease program and discussions for the vatiquinone Friedreich's ataxia program.

Upcoming R&D Day: Scheduled for December 2nd to discuss research program progress.

3Forward Guidance and Outlook

Revenue Guidance: Narrowed full-year 2025 revenue guidance to $750 million - $800 million, reflecting confidence in Sephience's performance and the DMD franchise's resilience.

Market Expansion: Plans for Sephience launch in Japan and Brazil, with expectations for regulatory approvals soon.

4Bad News, Challenges, or Points of Concern

Market Dynamics: Despite a strong launch, the company remains cautious as it navigates the early stages of Sephience's uptake, with potential fluctuations due to seasonal factors (holidays).

Competition: Concerns about the competitive landscape, particularly regarding patient switches from existing therapies like Palynziq.

Regulatory Risks: Ongoing FDA reviews for other products, including Translarna, which could impact future revenue streams.

5Notable Q&A Insights

Durability of Treatment: Management expressed confidence in the long-term uptake of Sephience, citing positive physician feedback and early patient responses.

Patient Demographics: The patient profile for Sephience includes a wide age range, with both treatment-naive and switch patients being prescribed.

Payer Engagement: Positive early interactions with U.S. payers, with favorable coverage policies enhancing access for patients.

Refill Rates: Early indications show strong refill rates among patients, particularly those who had previously struggled with other therapies.

Japan Market Potential: Anticipated pricing for Sephience in Japan may exceed that in the U.S. and Europe, reflecting its high value. Overall, PTC Therapeutics reported a strong quarter driven by the Sephience launch, with promising early metrics and a solid financial position, although it remains vigilant about market dynamics and competitive pressures.